Skip to main content
SpringerLink
Log in

Value of Endocrine Therapy for Early and Locally Advanced Prostate Cancer

  • Therapy In Practice
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Prostate-specific antigen-based screening and increased public awareness of prostate cancer have led to earlier detection of localised and potentially curable tumour stages. Nevertheless, disease recurrence after radical treatment of prostate cancer remains a problem for a considerable number of patients.

Endocrine therapy plays a role in the treatment of almost all stages of prostate cancer, either as definitive or as temporary therapy. Neoadjuvant hormonal treatment has its place mainly in the external beam radiotherapy setting, where it reduces target volume and adverse effects. When used prior to and during external beam radiotherapy, endocrine therapy has shown a survival advantage in the subset of patients with locally advanced prostate cancer (cT2-4, N0-1, M0) with Gleason scores 2–6.

Several studies have shown that adjuvant endocrine treatment is able to delay disease progression in any stage. There is, however, an ongoing controversy regarding the possible survival benefit of such treatment that has to be balanced against its considerable adverse effects and costs. Survival improvements associated with adjuvant hormonal treatments have mainly been seen in patients with lymph node metastases or those with a high probability of micrometastatic disease. Several large studies are under way to investigate the role of adjuvant treatment in the field of early prostate cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Similar content being viewed by others

References

  1. Smart CR. The results of prostate carcinoma screening in the U.S. as reflected in the surveillance, epidemiology, and end results program. Cancer 1997; 80: 1835–44

    Article  PubMed  CAS  Google Scholar 

  2. Zincke H, Oesterling JE, Blute ML, et al. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 1994; 152: 1850–7

    PubMed  CAS  Google Scholar 

  3. Gerber GS, Thisted RA, Chodak GW, et al. Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled analysis. Eur Urol 1997; 32: 385–90

    PubMed  CAS  Google Scholar 

  4. Bolla M. Adjuvant hormonal treatment with radiotherapy for locally advanced prostate cancer. Eur Urol 1999; 35 Suppl. 1: 23–6

    Article  PubMed  CAS  Google Scholar 

  5. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1591–7

    Article  PubMed  CAS  Google Scholar 

  6. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293–7

    CAS  Google Scholar 

  7. Kwak C, Jeong SJ, Park MS, et al. Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer. J Urol 2002; 168(3): 995–1000

    Article  PubMed  Google Scholar 

  8. Goodin S, Rao KV, DiPaola RS. State-of-the-art treatment of metastatic hormone-refractory prostate cancer. Oncologist 2002; 7(4): 360–70

    Article  PubMed  CAS  Google Scholar 

  9. Han M, Partin AW, Piantadosi S, et al. Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol 2001; 166: 416–9

    Article  PubMed  CAS  Google Scholar 

  10. Kolvenbag GJC, Iversen P, Newling DWW. Antiandrogen monotherapy: a new form of treatment for patients with prostate cancer. Urology 2001; 58 Suppl. 2A: 16–23

    Article  PubMed  CAS  Google Scholar 

  11. Iversen P, Tyrrell CJ, Kaisary AV, et al. Bicalutamide mono-therapy compared with castration in patients with non-metastatic locally advanced prostate cancer: 6.3 years of followup. J Urol 2000; 164: 1579–82

    Article  PubMed  CAS  Google Scholar 

  12. Boccardo F, Rubagotti A, Barichello M, et al. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study. J Clin Oncol 1999; 17: 2027–38

    PubMed  CAS  Google Scholar 

  13. Tyrrell CJ, Kaisary AV, Iversen P, et al. A randomised comparison of ‘Casodex’ (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 1998; 33: 447–56

    Article  PubMed  CAS  Google Scholar 

  14. Laufer M, Denmeade SR, Sinibaldi VJ, et al. Complete androgen blockade for prostate cancer: what went wrong? J Urol 2000; 164: 3–9

    Article  PubMed  CAS  Google Scholar 

  15. Klotz L. Hormone therapy for patients with prostate carcinoma. Cancer 2000; 88: 3009–14

    Article  PubMed  CAS  Google Scholar 

  16. Grossfeld GD, Small EJ, Lubeck DP, et al. Androgen deprivation therapy for patients with clinically localized (stages Tl to T3) prostate cancer and for patients with biochemical recurrence after radical prostatectomy. Urology 2001; 58 Suppl. 2A: 56–64

    Article  PubMed  CAS  Google Scholar 

  17. Scott WW. An evaluation of endocrine therapy plus radical prostatectomy in the treatment of advanced carcinoma of the prostate. J Urol 1964; 91: 97–102

    PubMed  CAS  Google Scholar 

  18. Tyrrell CJ. Adjuvant and neoadjuvant hormonal therapy for prostate cancer. Eur Urol 1999; 36: 549–58

    Article  PubMed  CAS  Google Scholar 

  19. Aus G, Abrahamsson PA, Ahlgren G, et al. Hormonal treatment before radical prostatectomy: a 3-year followup. J Urol 1998; 159: 2013–6

    Article  PubMed  CAS  Google Scholar 

  20. Soloway MS, Pareek K, Sharifi R, et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol 2002; 167: 112–6

    Article  PubMed  Google Scholar 

  21. Lee F, Siders DB, McHugh TA, et al. Neoadjuvant androgen ablation therapy prior to radical prostatectomy: results of a 3-year follow-up. Endocr Relat Cancer 1996; 3: 171–7

    Article  CAS  Google Scholar 

  22. Homma Y, Akaza H, Okada K, et al. Early results of radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation. The Prostate Cancer Study Group. Int J Urol 1999; 6: 229–37

    Article  PubMed  CAS  Google Scholar 

  23. Gleave ME, La Bianca SE, Goldenberg SL, et al. Long-term neoadjuvant hormone therapy prior to radical prostatectomy: evaluation of risk for biochemical recurrence at 5-year follow-up. Urology 2000; 56: 289–94

    Article  PubMed  CAS  Google Scholar 

  24. Scolieri MJ, Altman A, Resnick ML. Neoadjuvant hormonal ablative therapy before radical prostatectomy: a review. Is it indicated? J Urol 2000; 164: 1465–72

    CAS  Google Scholar 

  25. Zelefsky MJ, Harrison A. Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: reducing the potential morbidity of therapy. Urology 1997; 49 (3A Suppl.): 38–45

    Article  PubMed  CAS  Google Scholar 

  26. Blank KR, Whittington R, Arjomandy B, et al. Neoadjuvant androgen deprivation prior to transperineal prostate brachy-therapy: smaller volumes, less morbidity. Cancer J Sci Am 1999; 5: 370–3

    PubMed  CAS  Google Scholar 

  27. Pilepich MV, Winter K, John MJ, et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 50: 1243–52

    Article  PubMed  CAS  Google Scholar 

  28. Byar DP, Cole DK. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. Natl Cancer Inst Monogr 1988; 7: 165–70

    Google Scholar 

  29. Daniell HW. Osteoporosis due to androgen deprivation therapy in men with prostate cancer. Urology 2001; 58: 101–7

    Article  PubMed  CAS  Google Scholar 

  30. Zincke H, Bergstralh EJ, Larson-Keller JJ, et al. Stage Dl prostate cancer treated by radical prostatectomy and adjuvant hormonal treatment. Cancer 1992; 70: 311–23

    Article  PubMed  CAS  Google Scholar 

  31. The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial. Br J Urol 1997; 79: 235–46

    Article  Google Scholar 

  32. Kirk D, on behalf of the Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred hormone treatment for prostate cancer: how safe is androgen deprivation?, [abstract]. BJU Int 2000; 86 Suppl.: 220

    Article  Google Scholar 

  33. Messing EM, Manola J, Sarosdy M, et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999; 341: 1781–8

    Article  PubMed  CAS  Google Scholar 

  34. Eisenberger MA, Walsh PC. Early androgen ablation for prostate cancer? N Engl J Med 1999; 341: 1837–8

    Article  PubMed  CAS  Google Scholar 

  35. Seay TM, Blute ML, Zincke H. Long-term outcome in patients with pTxN+ adenocarcinoma of prostate treated with radical prostatectomy and early androgen ablation. J Urol 1998; 159: 357–64

    Article  PubMed  CAS  Google Scholar 

  36. Epstein JI, Partin AW, Sauvageot J, et al. Prediction of progression following radical prostatectomy: a multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol 1996; 20: 286–92

    Article  PubMed  CAS  Google Scholar 

  37. Kupelian P, Katcher J, Levin H, et al. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer. Urology 1996; 48: 249–60

    Article  PubMed  CAS  Google Scholar 

  38. Barry MJ, Albertsen PC, Bagshaw MA, et al. Outcomes for men with clinically nonmetastatic prostate carcinoma managed with radical prostatectomy, external beam radiotherapy, or expectant management: a retrospective analysis. Cancer 2001; 91: 2302–14

    Article  PubMed  CAS  Google Scholar 

  39. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997; 337: 295–300

    Article  PubMed  CAS  Google Scholar 

  40. Granfors T, Modig H, Damber JE, et al. Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study. J Urol 1998; 159: 2030–4

    Article  PubMed  CAS  Google Scholar 

  41. Pilepich MV, Caplan R, Byhardt RW, et al. Phase III trial of androgen suppression using goserelin in unfavourable prognosis carcinoma of the prostate treated with definitive radiotherapy-report of RTOG protocol 85-31. J Clin Oncol 1997; 15: 1013–21

    PubMed  CAS  Google Scholar 

  42. Lawton CA, Winter K, Murray K, et al. Updated results of the phase III radiation therapy oncology group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 49: 937–46

    Article  PubMed  CAS  Google Scholar 

  43. Arcangeli G, Saracino B, Micheli A, et al. Radiotherapy with or without androgen deprivation in the treatment of localized adenocarcinoma of the prostate. Am J Clin Oncol 1998; 21: 1–5

    Article  PubMed  CAS  Google Scholar 

  44. Hanks GE, Lu J, Machtay M, et al. RTOG Protocol 92-02: A phase III trial of the use of long-term androgen suppression following neoadjuvant hormonal cytoreduction and radio-therapy in locally advanced carcinoma of the prostate [abstract]. Proc ASCO 2000; 19: 327a

    Google Scholar 

  45. Wirth M, Tyrrell C, Wallace M, et al. Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression. Urology 2001; 58: 146–51

    Article  PubMed  CAS  Google Scholar 

  46. Wirth M, Frohmüller H, Marx F, et al. Adjuvant antiandrogenic treatment after radical prostatectomy in stage C prostate cancer-preliminary results of a randomized controlled multicenter trial [abstract]. J Urol 1997; 157: 1308

    Google Scholar 

  47. Prayer-Galetti T, Zattoni F, Capizzi A, et al., on behalf of the study group. Disease free survival in patients with pathological “C stage” prostate cancer at radical retropubic prostatectomy submitted to adjuvant hormonal treatment [abstract]. Eur Urol 2000; 38 Suppl. 4: 504

    Google Scholar 

  48. Zincke H, Lau W, Bergstralh E, et al. Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer. J Urol 2001; 166: 2208–15

    Article  PubMed  CAS  Google Scholar 

  49. Schröder FH, van den Ouden D. Management of locally advanced prostate cancer. 2. Radiotherapy, neoadjuvant endocrine treatment, update 1997–1999. World J Urol 2000; 18: 204–15

    Article  PubMed  Google Scholar 

  50. Pollack A, Zagars GK. Androgen ablation in addition to radiation therapy for prostate cancer: is there a true benefit? Semin Radiat Oncol 1998; 8: 95–106

    Article  PubMed  CAS  Google Scholar 

  51. Wirth M, Froehner M. A review of studies of hormonal adjuvant therapy in prostate cancer. Eur Urol 1999; 36 Suppl. 2: 14–9

    Article  PubMed  CAS  Google Scholar 

  52. Wirth MP, Froehner M. Perspectives in adjuvant treatment of prostate cancer. Urol Int 2002; 85: 1–5

    Article  Google Scholar 

  53. Wei JT, Dunn RL, Sandier HM, et al. Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol 2002; 20: 557–66

    Article  PubMed  Google Scholar 

  54. See WA, McLeod D, Iversen P, et al. The bicalutamide Early Prostate Cancer Program. Demography. Urol Oncol 2001; 6: 43–7

    Article  PubMed  Google Scholar 

  55. Wirth M. Delaying/reducing the risk of clinical tumour progression after primary curative procedures. Eur Urol 2001; 40 Suppl. 2: 17–23

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

There were no sources of funding used to assist in the preparation of this manuscript. Professor Wirth is the principal investigator in the ‘Bicalutamide Early Prostate Cancer Program’ which is funded by AstraZeneca.

Author information

Authors and Affiliations

  1. Department of Urology, University Hospital “Carl Gustav Carus”, Technical University of Dresden, Fetscherstrasse 74, Dresden, D-01307, Germany

    Manfred P. Wirth & Michael Froehner

Authors
  1. Manfred P. Wirth
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Froehner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Manfred P. Wirth.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wirth, M.P., Froehner, M. Value of Endocrine Therapy for Early and Locally Advanced Prostate Cancer. Drugs & Aging 20, 115–124 (2003). https://doi.org/10.2165/00002512-200320020-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200320020-00003

Keywords

Search

Navigation